CRNX
Crinetics Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.57
P/S
728.30
EV/EBITDA
-7.76
DCF Value
$-7.32
FCF Yield
-9.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
108.5%
Operating Margin
-9534.5%
Net Margin
-8585.2%
ROE
-41.5%
ROA
-41.0%
ROIC
-48.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.9M | $-122.8M | $-1.30 |
| FY 2025 | $7.7M | $-465.3M | $-4.95 |
| Q3 2025 | $143.0K | $-130.1M | $-1.38 |
| Q2 2025 | $1.0M | $-115.6M | $-1.23 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.31
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.